{
  "bill_id": "MA2025000H2432",
  "source_url": "http://custom.statenet.com/public/resources.cgi?id=ID:bill:MA2025000H2432&cuiq=93d84396-c63b-526a-b152-38b7f79b4cfd&client_md=e4f6fea4-27b4-5d41-b7d3-766fe52569f0",
  "versions": [
    {
      "date": "02/27/2025",
      "label": "Introduced",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:MA2025000H2432&verid=MA2025000H2432_20250227_0_I&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 MA H 2432</td> <td><table><tr><td class=\"label\">Author:</td> <td>Gentile</td></tr> <tr><td class=\"label\">Version:</td> <td>Introduced</td></tr> <tr><td class=\"label\">Version Date:</td> <td>02/27/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"left\">HOUSE No. 2432</p>\n   <p class=\"center\">The Commonwealth of Massachusetts</p>\n   <p class=\"center\">In the One Hundred and Ninety-Fourth General Court</p>\n   <p class=\"center\">(2025-2026)</p>\n  </div>\n  <a name=\"title_document_section\"></a><div class=\"title\">\n   <p class=\"left\">AN ACT to reduce incidence and death from pancreatic cancer</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"indent\">Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows: </p>\n   </span>\n   <p class=\"indent\">SECTION 1. Chapter 111 of the General Laws is hereby amended by adding the following section:-</p>\n   <p class=\"indent\">Section 245. (a) The department shall administer a comprehensive pancreatic cancer initiative to provide coordinated pancreatic cancer prevention, screening, education and support programs in the commonwealth. The department may develop and implement other initiatives regarding pancreatic cancer awareness, research and care that the department determines will further the purposes of this section.</p>\n   <p class=\"indent\">(b) There shall be a pancreatic cancer advisory council within the department. The council shall be appointed and convened by the commissioner and shall consist of 13 members representing interdisciplinary fields including, but not limited to, oncology, palliative care, medicine, nursing, social work, pharmacy, spirituality and the area of patient and family caregiver advocacy, including health professionals having expertise treating pancreatic cancer patients and their families; provided, at least 1 member shall be a representative of the Pancreatic Cancer Action Network and 1 member shall be a representative of the American Cancer Society Cancer Action Network. The commissioner may appoint other members that the commissioner deems appropriate. Council members shall serve for a period of 3 years at the pleasure of the commissioner. The members shall elect a chair and vice chair whose duties shall be established by the council. The department shall provide a place for regular meetings of the council, which shall meet at least monthly.</p>\n   <p class=\"indent\">Council members shall receive no compensation for their services but shall be allowed actual and necessary expenses in the performance of their council duties.</p>\n   <p class=\"indent\">The council shall:</p>\n   <p class=\"indent\">(1) Investigate and make recommendations for a system to certify and approve hospital systems that meet National Pancreatic Cancer Foundation criteria and post this information on an appropriate state website and on advocacy organization websites.</p>\n   <p class=\"indent\">(2) Identify institutions and hospital systems which could meet the criteria in areas that are geographically underserved and provide them with incentives to develop the necessary resources to comply in order to assure that all residents have access to hospitals that meet the criteria.</p>\n   <p class=\"indent\">(3) Investigate and make recommendations for the establishment of a multi-provider consortium to develop and disseminate amongst each other best practice algorithms, decision aids for electronic health record systems, and quality metrics for all phases of care in pancreatic cancer. The consortium shall partner with other entities including, but not limited to, patient organizations, National Institute of Health and the American Cancer Society Cancer Action Network to develop and maintain a portfolio of statewide clinical trials in pancreatic cancer.</p>\n   <p class=\"indent\">(4) Disseminate targeted communications to primary care providers and their office staff to connect them with the consortium members and resources which are local to their practices.</p>\n   <p class=\"indent\">(5) Utilize the local resources of the consortium members to fully operationalize existing state initiatives to identify existing cancer support services, survivorship care and counseling and to expand these initiatives to meet current needs.</p>\n   <p class=\"indent\">(6) Develop and support the use in all hospitals of a standard consent form for pancreatic cancer patients to consent to donate their tissue samples without restrictions for tissue collection and banking for research.</p>\n   <p class=\"indent\">(b) The department, in conjunction with the pancreatic cancer advisory council, shall conduct a comprehensive study to ascertain the prevalence and incidence of pancreatic cancer in the commonwealth, the unmet needs of persons with pancreatic cancer and their families, time-of-diagnosis statistics and likely risks for pancreatic cancer. Information collected by the study shall include, but not be limited to, the following:</p>\n   <p class=\"indent\">(1) germline testing results;</p>\n   <p class=\"indent\">(2) molecular tumor analysis in patients with metastatic disease;</p>\n   <p class=\"indent\">(3) hospitals treating the highest volume of pancreatic cancer patients;</p>\n   <p class=\"indent\">(4) information on stage of diagnosis;</p>\n   <p class=\"indent\">(5) treatment rendered, including chemotherapy, radiation therapy, surgical treatment, neoadjuvant and adjuvant therapy;</p>\n   <p class=\"indent\">(6) patient outcomes;</p>\n   <p class=\"indent\">(7) number of patients diagnosed who did not receive any treatment or palliative care; and</p>\n   <p class=\"indent\">(8) number of pancreatic resections performed at each hospital and associated outcomes.</p>\n   <p class=\"indent\">(c) The department, in conjunction with the pancreatic cancer advisory council, shall develop and implement a statewide public education and community outreach program to inform the general public about genetic risks, signs, symptoms, and pre-malignant conditions associated with pancreatic cancer, including new-onset diabetes, and the availability of clinical trials for those with pancreatic cancer. In developing and implementing the program, the commissioner shall consult with similar programs including, but not limited to, anti-tobacco, obesity and other premalignant conditions associated with pancreatic cancer. The department shall add pancreatic cancer to the list of diseases that its programs target with counseling for tobacco discontinuation, diet and weight management.</p>\n   <p class=\"indent\">SECTION 2. The commissioner of insurance shall survey health insurers in the commonwealth to ascertain coverage benefits of genetic testing for pancreatic cancer across health insurance plans, and present its findings to the committee on health care financing and the committee on financial services no later than June 30, 2026.</p>\n   <p class=\"indent\">SECTION 3. The center for health information and analysis shall conduct a review and update of its mandated benefit review of pancreatic cancer screenings as reported in the center&rsquo;s report titled &ldquo;Mandated Benefit Review of S.B. 471: An Act relative to pancreatic cancer screening,&rdquo; dated July 2014, including an update of the cost analysis for pancreatic cancer screening for high-risk individuals. The center shall present its findings and update to the committee on health care financing and the committee on financial services no later than June 30, 2026.</p>\n   <p class=\"indent\">SECTION 4. The initial meeting of the pancreatic cancer advisory council shall convene no later than 60 days after the effective day of this act.</p>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 MA H 2432 | | Author: | Gentile  \n---|---  \nVersion: | Introduced  \nVersion Date: | 02/27/2025  \n  \nHOUSE No. 2432\n\nThe Commonwealth of Massachusetts\n\nIn the One Hundred and Ninety-Fourth General Court\n\n(2025-2026)\n\nAN ACT to reduce incidence and death from pancreatic cancer\n\nBe it enacted by the Senate and House of Representatives in General Court\nassembled, and by the authority of the same, as follows:\n\nSECTION 1. Chapter 111 of the General Laws is hereby amended by adding the\nfollowing section:-\n\nSection 245. (a) The department shall administer a comprehensive pancreatic\ncancer initiative to provide coordinated pancreatic cancer prevention,\nscreening, education and support programs in the commonwealth. The department\nmay develop and implement other initiatives regarding pancreatic cancer\nawareness, research and care that the department determines will further the\npurposes of this section.\n\n(b) There shall be a pancreatic cancer advisory council within the department.\nThe council shall be appointed and convened by the commissioner and shall\nconsist of 13 members representing interdisciplinary fields including, but not\nlimited to, oncology, palliative care, medicine, nursing, social work,\npharmacy, spirituality and the area of patient and family caregiver advocacy,\nincluding health professionals having expertise treating pancreatic cancer\npatients and their families; provided, at least 1 member shall be a\nrepresentative of the Pancreatic Cancer Action Network and 1 member shall be a\nrepresentative of the American Cancer Society Cancer Action Network. The\ncommissioner may appoint other members that the commissioner deems\nappropriate. Council members shall serve for a period of 3 years at the\npleasure of the commissioner. The members shall elect a chair and vice chair\nwhose duties shall be established by the council. The department shall provide\na place for regular meetings of the council, which shall meet at least\nmonthly.\n\nCouncil members shall receive no compensation for their services but shall be\nallowed actual and necessary expenses in the performance of their council\nduties.\n\nThe council shall:\n\n(1) Investigate and make recommendations for a system to certify and approve\nhospital systems that meet National Pancreatic Cancer Foundation criteria and\npost this information on an appropriate state website and on advocacy\norganization websites.\n\n(2) Identify institutions and hospital systems which could meet the criteria\nin areas that are geographically underserved and provide them with incentives\nto develop the necessary resources to comply in order to assure that all\nresidents have access to hospitals that meet the criteria.\n\n(3) Investigate and make recommendations for the establishment of a multi-\nprovider consortium to develop and disseminate amongst each other best\npractice algorithms, decision aids for electronic health record systems, and\nquality metrics for all phases of care in pancreatic cancer. The consortium\nshall partner with other entities including, but not limited to, patient\norganizations, National Institute of Health and the American Cancer Society\nCancer Action Network to develop and maintain a portfolio of statewide\nclinical trials in pancreatic cancer.\n\n(4) Disseminate targeted communications to primary care providers and their\noffice staff to connect them with the consortium members and resources which\nare local to their practices.\n\n(5) Utilize the local resources of the consortium members to fully\noperationalize existing state initiatives to identify existing cancer support\nservices, survivorship care and counseling and to expand these initiatives to\nmeet current needs.\n\n(6) Develop and support the use in all hospitals of a standard consent form\nfor pancreatic cancer patients to consent to donate their tissue samples\nwithout restrictions for tissue collection and banking for research.\n\n(b) The department, in conjunction with the pancreatic cancer advisory\ncouncil, shall conduct a comprehensive study to ascertain the prevalence and\nincidence of pancreatic cancer in the commonwealth, the unmet needs of persons\nwith pancreatic cancer and their families, time-of-diagnosis statistics and\nlikely risks for pancreatic cancer. Information collected by the study shall\ninclude, but not be limited to, the following:\n\n(1) germline testing results;\n\n(2) molecular tumor analysis in patients with metastatic disease;\n\n(3) hospitals treating the highest volume of pancreatic cancer patients;\n\n(4) information on stage of diagnosis;\n\n(5) treatment rendered, including chemotherapy, radiation therapy, surgical\ntreatment, neoadjuvant and adjuvant therapy;\n\n(6) patient outcomes;\n\n(7) number of patients diagnosed who did not receive any treatment or\npalliative care; and\n\n(8) number of pancreatic resections performed at each hospital and associated\noutcomes.\n\n(c) The department, in conjunction with the pancreatic cancer advisory\ncouncil, shall develop and implement a statewide public education and\ncommunity outreach program to inform the general public about genetic risks,\nsigns, symptoms, and pre-malignant conditions associated with pancreatic\ncancer, including new-onset diabetes, and the availability of clinical trials\nfor those with pancreatic cancer. In developing and implementing the program,\nthe commissioner shall consult with similar programs including, but not\nlimited to, anti-tobacco, obesity and other premalignant conditions associated\nwith pancreatic cancer. The department shall add pancreatic cancer to the list\nof diseases that its programs target with counseling for tobacco\ndiscontinuation, diet and weight management.\n\nSECTION 2. The commissioner of insurance shall survey health insurers in the\ncommonwealth to ascertain coverage benefits of genetic testing for pancreatic\ncancer across health insurance plans, and present its findings to the\ncommittee on health care financing and the committee on financial services no\nlater than June 30, 2026.\n\nSECTION 3. The center for health information and analysis shall conduct a\nreview and update of its mandated benefit review of pancreatic cancer\nscreenings as reported in the center's report titled \"Mandated Benefit Review\nof S.B. 471: An Act relative to pancreatic cancer screening,\" dated July 2014,\nincluding an update of the cost analysis for pancreatic cancer screening for\nhigh-risk individuals. The center shall present its findings and update to the\ncommittee on health care financing and the committee on financial services no\nlater than June 30, 2026.\n\nSECTION 4. The initial meeting of the pancreatic cancer advisory council shall\nconvene no later than 60 days after the effective day of this act.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": true
    }
  ]
}